Cardiopulmonary Bypass clinical trials at UCSF

1 research study open to eligible people

Cardiopulmonary bypass is used to support heart and lung function during surgery. UCSF is conducting a study to see if the drug ravulizumab can reduce kidney problems in patients undergoing this procedure. The trial compares the drug's effects to a placebo.

Showing trials for

  • ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

    open to eligible people ages 18-90

    The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

    San Francisco, California and other locations

Last updated: